Physician profile
David E Benton
NPI 1952319865
$17,622.24
in general payments reported to CMS, 2019-2025
75 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,785 · 2020: $2,087 · 2021: $3,805 · 2022: $2,346 · 2023: $2,442 · 2024: $2,056 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,591 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,590.96 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,019.04 | 2019-2025 | Vraylar, Synthroid, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $2,015.59 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,797.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,384.08 | 2020-2021 | |
| Glaxosmithkline, LLC. | $1,206.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Pfizer INC. | $1,191.73 | 2019-2025 | |
| Lilly USA, LLC | $1,084.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $653.41 | 2019-2025 | Otezla, Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $536.09 | 2019-2025 | Zoryve |
| Abbott Laboratories | $491.92 | 2020-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.57 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $350.88 | 2019-2025 | Belsomra, Steglatro, Gardasil 9 |
| Amarin Pharma, INC. | $314.81 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $296.00 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $247.55 | 2019-2021 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Benton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.